GH250117P44000
- 0.00
- 0.000.00%
Guardant Health Newsroom
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
Express News | Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute's Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $34
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Guardant Health (NASDAQ:GH Shareholders Incur Further Losses as Stock Declines 8.9% This Week, Taking Three-year Losses to 68%
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
Express News | Cota and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development With Real-World Clinicogenomic Data and AI Analytics
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development With Real-World Clinicogenomic Data and AI Analytics
Express News | Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
Express News | Guardant Health Inc : Guggenheim Raises Target Price to $40 From $36
Manulife Singapore Partners With Guardant Health to Provide Cancer Treatments
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Express News | Natera Issues Statement on Guardant Health Litigation